Detecting measurable residual disease beyond 10−4 by an IGHV leader-based NGS approach improves prognostic stratification in CLLPaul J. Hengeveld, Anton W. Langerak, François G. Kavelaars et al.|Blood|2022Cited by 24
ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic LeukemiaMatthew S. Davids, Othman Al‐Sawaf, Kirsten Fischer et al.|Blood|2021Cited by 12